Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Daiichi versus...

    Daiichi versus Ranbaxy: Singapore SC allows Harish Salve to represent the case

    Written by savita thakur thakur Published On 2017-11-02T09:36:01+05:30  |  Updated On 2 Nov 2017 9:36 AM IST
    Daiichi versus Ranbaxy: Singapore SC allows Harish Salve to represent the case

    New Delhi: The Singapore Supreme Court has allowed the Indian lawyer Harish Salve to represent the Singh brothers Malvinder Singh and Shivinder Singh in the Ranbaxy-Daiichi arbitration case.


    This is the first time an Indian lawyer has been allowed to fight a case in Singapore. Singapore’s Court of Appeal has allowed Salve to appear “on behalf of the majors and the minors for the Singapore award challenge proceedings”, a spokesperson for RHC Holding Pvt Ltd, the Singhs’ holding company, told ET.


    Medical Dialogues team had earlier reported that the Singapore Supreme Court had disallowed senior advocate Harish Salve from appearing on behalf of corporate sellers of Ranbaxy against the case filed by the Daiichi Sankyo for not revealing risks involved in the buyout by Ranbaxy owners.


    Earlier, the arbitration court in Singapore directed former promoters of Ranbaxy laboratories Ltd, Malvinder Mohan Singh, and Shivinder Mohan Singh to pay damages worth Rs.2,562.78 crore to Japan’s Daiichi Sankyo Co. Ltd.


    Read also: Singapore SC Disallows Harish Salve to represent Ranbaxy Owners in Daiichi Case


    The court now allowed Harish Salve for the “Special qualifications or experience for the purpose of the case."


    The judge also held that the evidence on Indian law pertaining to the case was not unusually complex or difficult “so as to be beyond the competence of local counsel”, and that allowing foreign counsel to argue in cases where foreign law was to be proved would set an “undesirable precedent," reports Bar and Bench


    The Singh brothers are challenging the Daiichi's an arbitration tribunal award case in which the Singapore court had directed former promoters of Ranbaxy Laboratories Ltd, Malvinder Mohan Singh, and Shivinder Mohan Singh to pay damages worth Rs.2,562.78 crore to Japan’s Daiichi Sankyo Co. Ltd for information regarding wrongdoing at Ranbaxy at the time of the sale.


    Read Also: Ex-Ranbaxy owners to pay Rs 2,600 Crores to Daiichi for concealing facts


    “This is the first case of an Indian counsel representing in Singapore Court, otherwise it is only local lawyers or Queen’s Counsel who have been allowed,” a lawyer in Singapore courts told ET


    The Court is now expected to fix a date for hearing the case, which was earlier due to come up in November


    arbitration casedaiichiFortisHarish Salveindian lawyerJapanese firmMalvinder SinghRanbaxyShivinder SinghSingaporeSupreme Court
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok